Proteomics and personalized medicine: a focus on kidney disease

Expert Rev Proteomics. 2019 Sep;16(9):773-782. doi: 10.1080/14789450.2019.1659138. Epub 2019 Aug 23.


Introduction: Inter-individual variability in response to drug treatment has induced an increased demand for decisions via personalize medicine. Also, the contribution of proteomics to the era of personalized medicine would seem to be vital in improving therapeutic outcomes. Areas covered: We review validated biomarkers discovered by proteomics techniques and their use in personalized medicine with the focus on kidney diseases. We discuss this topic with a special emphasis on recent publications and relevant initiatives and depict some limitations that remain for personalized medicine. Expert opinion: The development of highly accurate biomarkers is essential for optimizing the management of kidney diseases. Various biomarkers of kidney diseases have been identified using proteomic techniques. However, only a few of these biomarkers showed the potential to be used in clinical practice concerning personalized medicine. Therefore, it becomes evident that the combination of multiple biomarkers confers higher accuracy and the ability to depict complex pathophysiological conditions, a prerequisite for personalized treatment. CKD273, a multimarker panel for early CKD detection may serve as a first example for personalized medicine in nephrology. Based on this successful example, proteomics is expected to develop into the key technology to guide personalized intervention.

Keywords: chronic kidney disease; personalized medicine; proteomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / metabolism*
  • Early Diagnosis*
  • Humans
  • Kidney Diseases / diagnosis*
  • Kidney Diseases / genetics
  • Kidney Diseases / pathology
  • Precision Medicine / trends
  • Proteomics*


  • Biomarkers